OVARIAN CANCER

Treatment of ovarian cancer chemotherapy new program Researchers reported that the joint use of both cisplatin and paclitaxel chemotherapy drug for ovarian cancer achieved better clinical remis...

Previous accept carboplatin multidrug chemotherapy in patients with recurrent ovarian cancer Carboplatin and Paclitaxel weekly therapy is safe and effective Kikuchi, the Japanese report, have received platinum multidrug chemotherapy for recurrent ovarian cancer Japanese women, a weekly carboplati...

Ovarian cancer is the female reproductive system cancer one of the three, as misprision of clinical symptoms, the lack of an effective method for early diagnosis, over 80% of patients had treatment for late mortality gynecologic malignancies in the first place. CA-125 tumor marker specificity is not strong, there false positive, we can not separate screening for ovarian cancer. High-throughput protein groups for the study of information technology and biological tools for ovarian cancer biomarkers of mass rapid screening provided a powerful weapon.

Protein-protein and protein <BR> <BR> group (the term "proteome by <BR> Wilkins was first proposed in 1994, which refers to a species of the gene coding for a full protein. Theoretically, a species only a genome, but there are many body cells, in the implementation of a function, not need full genome expression or different cells express the same protein group. DNA variation, mRNA splicing, post-transcriptional expression of the modified gene function and regulation of protein and other factors could lead to the expression changes. Group of protein (protein proteomics "is based on the study group, through the corresponding protein analysis technology, research body in a particular state of all forms of protein expression.

Protein Research Group in the following three aspects: (a) large-scale protein identification and post-transcriptional modification of the micro-studies; (2) that differences in protein group, compared with the normal state of the disease protein expression differences, biological marker for disease diagnosis; (3) protein - protein interaction studies.

Screening tumor markers

Cure cancer is the key to early diagnosis, the diagnostic value for a specific tumor marker protein group is the focus of study. Plasma protein with a clear pedigree could change as early detection of ovarian cancer indicators, Rai, collected 43 cases before surgery serous ovarian cancer patients (11 patients with stage I, II three cases, 29 patients with Stage III) and 38 patients with non-cancer controls plasma specimens, specimens of these protein expression spectrum analysis of biological information, establishes three types of biological marker, and its comparison with CA 125.

Results showed that although a single biological marker for ovarian cancer are not predict sensitivity and CA 125, CA 125 and the three joint application, specificity of 94%, while sensitivity is also as high as 94%, significantly better than using CA-125, indicating that the protein can be effective choice of eggs Biological markers of cancer nests.

Petricoin, 50 cases of ovarian cancer patients and 50 healthy controls serum study by the group include a five differentially expressed proteins and still correctly identify cancer and non-cancer protein expression profiles. Another unknown serum of 116 cases (including 50 patients with epithelial ovarian cancer) test found 50 cases of ovarian cancer patients (including 18 patients with stage I) of serum all be correctly identified 66 cases in 63 cases of ovarian cancer were excluded. Its sensitivity was 100%, specificity 95%, positive predictive value was 94%, and the same with CA 125 serum samples of the positive predictive value was 35%.

Kozak, 109 cases of ovarian cancer, 19 patients with benign ovarian tumors and 56 healthy controls serum for analysis, screening a group of protein markers in three groups, and using unknown serum test. Results showed that the three joint application, 22 cases of ovarian cancer patients, 21 cases were correctly diagnosed, six cases of low malignant potential tumors were correctly diagnosed, six cases of benign tumor in five cases ruled out ovarian cancer.

Mok application of microarray technology Prostasin (prostate secretory a serine proteinase) in the expression of ovarian cancer cells, through qualitative and quantitative analysis found that Prostasin in ovarian interstitial cells and the expression was significantly higher than normal ovarian epithelial cells in patients with ovarian cancer were significantly higher Prostasin in the control group, and patients with ovarian cancer were significantly lower Prostasin. Further study found that Prostasin combined with CA 125, the non-mucinous epithelial ovarian cancer diagnostic specificity was 94%, a sensitivity of 92%. Researchers believe that Prostasin by ovarian cancer cells and released into the blood synthesis, is a new marker of ovarian cancer.

Apart from the group of proteins that can detect cancer cells secreted proteins, can also be used to study the source of tumor markers. Ye and selected a molecular weight of about 11.7 Kd protein markers in the plasma, was identified as haptoglobin (Hp alpha alpha ", RT-PCR and western blot method was not detected in ovarian cancer Hp α expression speculate in the serum of patients with ovarian cancer Hp α increased specificity and crack Xie enzyme or protein interactions related to Hp cracking. While Hp α is not secreted by ovarian cancer cells, but can be used in the diagnosis of ovarian cancer markers, separate application sensitivity of 64%, specificity of 90%; Combined with CA 125 for ovarian cancer diagnostic sensitivity of 91%, specificity of 95%.

These studies suggest that the protein group of ovarian cancer screening and early diagnosis of a broad clinical application.

PNAS: The United States and find ovarian cancer early detection methods Researchers in the United States on the 10th reported that they found a blood-screening early detection of ovarian cancer and new ways to i...

Protein detection help in the early diagnosis of ovarian cancer The latest research report, researchers in the search for a new blood test to help early diagnosis of ovarian cancer progress, the rate of p...

Daqing City in Heilongjiang hospital recently adopted a new therapy combining traditional Chinese and western medicine, ultrasound-guided p...

Early signs of ovarian cancer When ovarian cancer is often diagnosed late has come. As of early ovarian cancer five-year survival rate was 70% to 90%, while the terminal...

Interferon combined with the chemotherapy treatment of ovarian cancer Austria adopted interferon combination of chemotherapy and women's ovarian cancer treatment, and achieved better than chemotherapy alone...

Early detection of ovarian cancer is the new law Ovarian cancer early detection difficult until the inspection was coming out of the general cancer has spread, treatment too late. Research...

Early ovarian cancer surgical staging important clinical value

Taxol and carboplatin Joint effective treatment of advanced ovarian cancer

Tags: age, anti, benign, blood, body, cancer, cases, cell, cells, clinical, diagnosis, early, eat, eggs, gene, group, groups, increased, malignant, mass, method, ovarian, patients, positive, prostasin, protein, rate, screening, study, surgery, symptoms, treatment, tumor, tumors